1. Бурмистрова Т.А., Зыкова Т.А. Возможности таурина в лечении метаболических и репродуктивных нарушений у мужчин. Сб. материалов XIX Российского Национального конгресса «Человек и лекарство». М., 2012; с. 50.
2. Barker DJ. The origins of the developmental origins theory. J Intern Med 2007; 261: 412–7.
3. Aerts L, Assche Van FA. Taurine and taurine-deficiency in the perinatal period. J Perinat Med 2002; 30: 281–6.
4. Militante JD, Lombardini JB. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids 2002; 23: 381–93.
5. Cherif H, Reusens B, Ahn MT et al. Effects of taurine on the insulin secretion of rat fetal islets from dams fed a low-protein diet. J Endocrinol 1998.
6. Pacioretty L, Hickman MA, Morris JG, Rogers QR. Kinetics of taurine depletion and repletion in plasma, serum, whole blood and skeletal muscle in cats. Amino Acids 2001; 21: 417–27.
7. Roysommuti S, Suwanich A, Lerdweeraphon W et al. Sex dependent effects of perinatal taurine exposure on the arterial pressure control in adult offspring. Adv Exp Med Biol 2009; 643: 135.
8. Arany EB, Romanus SP, Remacle C et al. Taurine supplement in early life altered islet morphology, decreased insulitis and delayed the onset of diabetes in non-obese diabetic mice. Diabetolog 2004; 47: 1831–7.
9. Economides DL, Nicolaides KH, Gahl WA et al. Plasma amino acids in appropriate- and small for gestational age fetuses. Am J Obstet Gynecol 1989; 161: 1219–27.
10. Sturman JA. Taurine in development. J Nutr 1988; 118: 1169–76.
11. Warskulat U, Heller-Stilb B, Oermann E et al. Phenotype of the taurine transporter knockout mouse. Methods Enzymol 2007; 428: 439–58.
12. Philipps AF, Holzman IR, Teng C, Battaglia FC. Tissue concentrations of free amino acids in term human placentas. Am J Obstet Gynecol 1978; 131: 881–7.
13. Desforges M, Parsons L, Westwood M et al. Taurine transport in human placental trophoblast is important for regulation of cell differentiation and survival. Cell Death Dis 2013; 21 (4): 559.
14. Kim KS, Oh da H, Kim JY et al. Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. Exp Mol Med 2012; 44 (11): 665–73.
15. Takashi I, Schaffer SW, Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 2012; 42 (5): 1529–39.
16. Ворохобина Н.В., Кузнецова А.В. Применение Дибикор® у больных сахарным диабетом типа 2 и метаболическим синдромом. РМЖ. 2010; 18 (28): 1–4.
17. Доскина Е.В., Аметов А.С. Современные возможности комплексной терапии у женщин менопазуального возраста с метаболическим синдромом. Доктор.Ру. 2009; 6: 50.
18. Нечаева Г.И., Ряполова Е.А., Друк И.В. Эффективность и переносимость таурина у пациентов с сахарным диабетом типа 2 и диастолической дисфункцией левого желудочка. Лечащий врач. 2011; 11.
19. Северина Т.И., Попкова Е.Н., Трельская Н.Ю., Емельянов В.В. Клиническая и метаболическая эффективность препарата Дибикор у больных сахарным диабетом типа 2. Фарматека. 2011; 5: 126–9.
20. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. Опыт применения Дибикора при сахарном диабете типа 2. Сахарный диабет. 2007; 1.
21. Chen X, Sebastian BM, Tang H et al. Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology 2009; 49 (5): 1554–62.
22. Kumpf VJ. Parenteral nutrition-associated liver disease in adult and pediatric patients. Nutr Clin Pract 2006; 21 (3): 279–90.
23. Сизова О.С. Клинико-экспериментальное исследование возможности фармакологической регуляции активности цитохрома P-4503A4 у больных онихомикозом. Автореф. дис. … канд. мед. наук. М., 2011.
24. Лосева Н.В., Моисеенко Е.Е. Опыт применения препарата Дибикор в комплексной терапии неалкогольной жировой болезни печени. Фарматека. 2010; 13: 63–7.
25. Park SH, Lee H, Park KK et al. Taurine-responsive genes related to signal transduction as identified by cDNA microarray analyses of HepG2 cells. J Med Food 2006; 9 (1): 33–41.
26. Chen YX, Zhang XR, Xie WF, Li S. Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat Dis Int 2004; 3 (1): 106–9.
27. Nakamura T, Ogasawara M, Koyama I et al. The protective effect of taurine on the biomembrane against damage produced by oxygen radicals. Biol Pharm Bull 1993; 16 (10): 970–2.
28. Toyoda A, Iio W. Antidepressant-like effect of chronic taurine administration and its hippocampal signal transduction in rats. Adv Exp Med Biol 2013; 775: 29–43.
29. Caletti G, Olguins DB, Pedrollo EF et al. Antidepressant effect of taurine in diabetic rats. Amino Acids 2012; 43 (4): 1525–33.
30. Нечаева Г.И., Ряполова Е.А., Друк И.В. Эффективность и переносимость таурина у пациентов с сахарным диабетом типа 2 и диастолической дисфункцией левого желудочка.  Лечащий врач. 2011; 11.
31. Наумов В.В. Сравнительная эффективность и аспекты механизма действия тауфона и манинила у больных сахарным диабетом типа 2. Автореф. дис. … канд. мед. наук. Волгоград, 2004.
32. Das J, Roy A, Sil PC. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: a review. Food Funct 2012; 3 (12): 1251–64.
33. Winiarska K, Szymanski K, Gorniak P et al. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochim 2009; 91 (2): 261–70.
34. Franconi F, Bennardini F, Mattana A et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 1995; 61 (5): 1115–9.
35. Ogasawara M, Nakamura T, Koyama I et al. Reactivity of taurine with aldehydes and its physiological role. Chem Pharm Bull Tokyo 1993; 41: 2172–5.
36. Pennathur S, Heinecke JW. Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 2007; 7: 257–64.
37. Das J, Vasan V, Sil PC. Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis. Toxicol Appl Pharmacol 2012; 258 (2): 296–308.
38. Ulrich-Merzenich G, Zeitler H, Vetter H, Bhonde RR. Protective effects of taurine on endothelial cells impaired by high glucose and oxidized low density lipoproteins. Eur J Nutr 2007; 46: 431–8.
39. Higo S, Miyata S, Jiang QY et al. Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats. Kobe J Med Sci 2008; 54: e35–45.
40. Zeng K, Xu H, Mi M et al. Effects of taurine on glial cells apoptosis and taurine transporter expression in retina under diabetic conditions. Neurochem Res 2010; 35: 1566–74.
41. Zeng K, Xu H, Chen K et al. Effects of taurine on glutamate uptake and degradation in Mu¨ller cells under diabetic conditions via antioxidant mechanism. Cell Neurosci 2010; 45: 192–9.
42. Stevens MJ, Lattimer SA, Kamijo M et al. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetolog 1993; 36: 608–14.
43. Li F, Obrosova IG, Abatan O et al. Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of STZ-D rats. Am J Physiol Endocrin Metab 2005; 288: e29–36.
44. Pop-Busui R, Sullivan KA, Huysen Van C et al. Depletion of taurine in experimental diabetic neuropathy: implications for nerve, 2001.
45. Murakami S, Kondo Y, Tomisawa K, Nagate T. Prevention of atherosclerotic lesion development in mice by taurine. Drugs Exp Clin Res 1999; 25: 227–34.
46. Рогова Н.В., Бочарников А.А. Зависимость выраженности дезагрегационных эффектов Дибикора от его плазменных концентраций у больных сахарным диабетом типа 2. Волгоград: Изд-во ВолГМУ, 2008; 1 (25): 45–8.
47. Yamori Y, Liu L, Ikeda K et al. Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens Res 2001; 24: 453–7.
48. Militante JD, Lombardini JB, Schaffer SW. The role of taurine in the pathogenesis of the cardiomyopathy of insulin-dependent diabetes mellitus. Cardiovasc Res 2000; 46: 393–402.
49. Li C, Cao L, Zeng Q et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by down regulating angiotensin II type 2 receptor expression. Cardiovasc Drugs Ther 2005; 19: 105–12.

А.С.Аметов, И.И. Кочергина, Е.П.Елизарова

Кафедра эндокринологии и диабетологии ГБОУ ДПО РМАПО Минздрава РФ